Search Results

Hengyang New Radiopharmaceutical Isotope and Drug Industrialization Project Officially Launched

On August 22, the groundbreaking ceremony for the Hengyang New Radiopharmaceutical Isotope and Drug Industrialization Project was held in Hengyang, Hunan Province. Officials from Hengyang City and Zhuhui District, representatives from relevant colleges of the University of South China, investment institutions, and relevant personnel from New Radiopharmaceutical Medical attended the event. Cai Jiming, Chairman and President of New Radiopharmaceutical Medical, stated at the ceremony that the project's landing in Hengyang represents an important strategic layout for the company's nuclear medicine business. From contract signing to construction commencement, the project has received support from local governments, partners, and relevant organizations. The company will leverage this project as an opportunity to continue advancing the transformation of innovative achievements in the fields of medical isotopes and radiopharmaceuticals. Wang Jing, Deputy Mayor of Hengyang City, stated that Hengyang...

2026-08-22

CNNC Particle and Beijing Institute of Medical Device Testing Carry Out Joint Learning and Co-building Activity

On August 20, CNNC Particle and the Beijing Institute of Medical Device Testing carried out a joint learning and co-building activity. Representatives from both sides engaged in in-depth discussions on topics such as Party building leading business development, joint development of technical standards, and enhancement of inspection and testing capabilities. Wu Wei, Secretary of the Party Branch and Director of CNNC Particle, Wu Kechun, Deputy Secretary of the Party Committee of the Institute, and more than twenty Party member representatives from both sides participated in the event. At the beginning of the event, the CNNC Particle delegation visited the Institute's laboratories to gain first-hand understanding of its technical capabilities and research progress in inspection and testing. The Institute's advanced experimental platforms and technologies left a deep impression on the visitors. During the discussion session, Wu Kechun and Wu Wei delivered speeches respectively. Both sides...

2026-08-22

Cubresa Brain PET Scanner Receives FDA 510(k) Clearance, Integrates with Existing PET/MR Systems

Molecular imaging technology company Cubresa Inc. announced on August 20 that its Cubresa BrainPET™ scanner has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). According to the company, the Cubresa BrainPET™ is a positron emission tomography (PET) device specifically designed for brain imaging and can be integrated into existing Siemens Biograph mMR MR/PET systems. The device enables healthcare institutions to perform simultaneous PET/MR brain imaging on existing MRI infrastructure, capturing molecular and anatomical information without the need to purchase a separate whole-body hybrid imaging system. Cubresa founder and CEO James ...

2026-08-22

South Korea's Asan Medical Center Develops AI-Based Radiopharmaceutical Therapy Platform with U.S. Institutions

The research team at Asan Medical Center in Seoul announced on the 21st that it has recently been selected for the "2026 Korea-U.S. Innovative Outcomes R&D New Support Project" organized by the Ministry of Health and Welfare, and will collaborate with U.S. research institutions to develop an artificial intelligence-based radiopharmaceutical therapy platform aimed at exploring new treatment strategies for solid tumors that respond poorly to conventional therapies. The team is composed of professors including Myung Seung-jae from the Department of Gastroenterology, Oh Seung-jun from the Department of Nuclear Medicine, Ryu Chang-hoon from the Department of Oncology, Jung Byung-kwan from the Department of Pathology, and Son Byung-ho from the Department of Breast Surgery at Asan Medical Center. The project will combine Asan Medical Center's large-scale clinical and pathological data, Emory University's AI-based digital pathology analysis technology, and Case Western Reserve University and University Hospitals Cleveland Medical Center's pathological and clinical research capabilities.

2026-08-22

Indiana University Health Establishes Center of Excellence in Theranostics to Advance Precision Targeted Cancer Therapy

Indiana University Health is establishing a new Center of Excellence in Theranostics, planning to provide cancer patients with more personalized diagnostic and treatment services through theranostic technologies. The project combines advanced medical imaging, precision diagnostics, and image-guided targeted therapy, aiming to enhance access to relevant medical services for patients in Indiana. Partial funding comes from a $20 million donor contribution, with Indiana University providing matching funds to bring total donations to $40 million. According to Indiana University, theranostics is a technological approach that integrates diagnosis and treatment. Clinically, advanced imaging techniques are first used...

2026-08-23

Global PET Market Expected to Reach $2.81 Billion by 2035, PET-CT Remains Dominant

A market research report shows that the global Positron Emission Tomography (PET) market size is expected to increase from $1.86 billion in 2025 to $2.81 billion by 2035, with a compound annual growth rate (CAGR) of 4.26% from 2026 to 2035. Increased demand for cancer diagnosis, expanded application of hybrid imaging technologies such as PET-CT and PET-MRI, and continued development of molecular imaging technologies are considered major factors driving market growth. The report notes that PET scans are being increasingly used in scenarios such as cancer detection and treatment evaluation, cardiac disease assessment, and diagnosis of neurological and psychiatric disorders. Meanwhile, population aging, rising healthcare expenditures, and growing demand for early screening are also driving...

2026-08-23

Construction of Radiotherapy and Radiosurgery Center Completed at Bulgaria's St. Ivan Rilski University Hospital

All construction and repair work for the new Radiotherapy and Radiosurgery Center at Bulgaria's St. Ivan Rilski University Hospital has been fully completed. According to the hospital, a latest-generation medical linear accelerator has been installed in the center, capable of sub-millimeter patient positioning accuracy. The equipment was delivered by the Ministry of Health under the National Recovery and Resilience Plan, as part of the investment project for the modernization of the national system for diagnosis and treatment of oncological diseases, funded by the European Commission's Recovery and Resilience Facility. The device is a TrueBeam-EDGE linear accelerator manufactured by Varian Medical Systems, equipped with BrainLab's ExactTrac Dynamic system, valued at 5.1 million...

2026-08-21

Five New Oncology Diagnostic and Treatment Devices at Bulgaria's ISUL Hospital Expected to Launch This Autumn

Queen Joanna - ISUL University Hospital in Bulgaria expects to begin operating five new devices for imaging diagnosis and treatment of oncological diseases starting early this autumn. The hospital stated that patients will be able to use these high-tech devices after the relevant licensing and approval procedures are completed. Source: Queen Joanna University Hospital - ISULThe newly added equipment is deployed in the imaging diagnostics department and the radiation oncology department. Among them, the radiation therapy department will be equipped with a TrueBeam v4.1 medical linear accelerator, primarily used for radiotherapy and radiosurgery. This device can deliver high-energy radiation to tumor tissue with greater precision, supporting high-precision dose planning to achieve the required therapeutic effect while minimizing radiation exposure to healthy tissues and organs surrounding the tumor.

2026-08-21

South Korea's National Assembly Passes Amendments on Radiation Disaster Response, Strengthening the Treatment System for Radiation Victims

The South Korean National Assembly held a plenary session on the 20th and passed two livelihood bills proposed by Rep. Yoon Jun-byeong, a member of the Parliamentary Agriculture, Food, Rural Affairs and Fisheries Committee. The bills concern the establishment of a radiation disaster response system and adjustments to the support system for surviving family members of national meritorious persons. Under the amendments passed, the Korea Atomic Energy Research Institute will be granted the qualification to operate as a specialized hospital for treating radiation victims. This arrangement aims to further improve the national medical safety net, enabling industrial radiation workers and victims of accidental radiation incidents to receive faster and more systematic treatment and rehabilitation support. Meanwhile, another amendment was also passed. This amendment, in accordance with the Constitutional Court's ruling of nonconformity, abolishes the provision that prioritized age as the sole criterion in the payment of survivor benefits to families of national meritorious persons of the same rank. After the relevant institutional adjustment, greater emphasis will be placed on safeguarding the rights of low-income households to reduce blind spots in welfare support.

2026-08-21

Iran Restarts Cyclotron to Boost Supply of Radiopharmaceuticals for Cancer Diagnosis and Treatment

Iranian nuclear industry experts have recently resumed operation of a cyclotron used in nuclear medicine, which can produce radioisotopes needed for cancer diagnosis and treatment. According to plans, by the end of Iran's Seventh Development Plan, i.e., March 2029, Iran will have seven such centers to expand domestic supply capacity for medical radioisotopes. A cyclotron is a type of particle accelerator that can be used to produce nuclear medicine radioisotopes and further prepare radiopharmaceuticals. These drugs can be used for the detection, diagnosis, and monitoring of malignant tumors. Data shows that related products produced domestically in Iran include FDG and F-PSMA, primarily serving nuclear medicine diagnosis and treatment for various cancers...

2026-08-21

Norroy Bioscience's 68Ga-NYM096 Receives FDA Breakthrough Therapy and Fast Track Designations

China-based Norroy Bioscience announced on August 19 that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy and Fast Track designations to its radiopharmaceutical imaging agent 68Ga-NYM096. The agent is a PET imaging tracer targeting carbonic anhydrase IX (CAIX), intended for imaging clear cell renal cell carcinoma (ccRCC). According to the company, 68Ga-NYM096 is being developed as a non-invasive PET imaging tool to characterize renal masses detected by CT or MRI and to help distinguish clear cell renal cell carcinoma from other non-ccRCC renal lesions. Clear cell renal cell carcinoma is the most common subtype of renal cell carcinoma...

2026-08-21

Atom High-Tech and CNNC Headway Visit Tsinghua University for Business Cooperation Exchange

On August 17, Luo Xu, General Manager of Atom High-Tech, and Liu Wen, Chairman of CNNC Headway, led a delegation to Tsinghua University for a business cooperation exchange with the School of Biomedical Engineering. Hu Ye, Dean of the School of Biomedical Engineering, and Ma Kai, Associate Professor of the School, attended the exchange. The visit aimed to leverage the research and talent advantages of a top-tier university, promote deep integration of industry, academia, and research, and jointly explore new cooperation opportunities in the fields of nuclear medicine and biomedical engineering. During the exchange meeting, Atom High-Tech and CNNC Headway respectively introduced their corporate development histories, core business layouts, and future strategic plans. Subsequently, Dean Hu Ye and Associate Professor Ma Kai respectively introduced...

2026-08-21

Brazilian CancerThera Delegation Visits Uruguay's CUDIM to Advance Theranostics Cooperation in Oncology

Following the institutional partnership established between CEPID CancerThera and the Uruguayan Center for Molecular Imaging (CUDIM) in February this year, a Brazilian delegation visited Montevideo, Uruguay, from July 27 to 29 to advance the transformation of the memorandum of understanding into a concrete work plan. The visit focused on multicenter clinical trials, preclinical research, theranostics in oncology, and educational cooperation. During the visit, Brazilian researchers held working meetings with the CUDIM team, covering multiple aspects of oncology research development. CUDIM was represented by its General Director Alarico Rodriguez, as well as radiopharmacist and Technical Director of Radiopharmacy, Dr. Eduardo Osvaldo Savio Queve...

2026-08-20

Akiram Therapeutics and ITM Sign Lutetium-177 Supply Agreement to Support Radiopharmaceutical Development for Solid Tumors

Akiram Therapeutics, a Swedish clinical-stage biotechnology company, and ITM Isotope Technologies Munich SE, a German radiopharmaceutical biotechnology company, recently announced the signing of a supply agreement. Under the agreement, ITM will supply no-carrier-added lutetium-177 (nca Lu-177) to Akiram to support the clinical development of its targeted antibody-radionuclide conjugate, 177Lu-AKIR001 (AKIR001). AKIR001 is Akiram's lead radiopharmaceutical candidate, currently being investigated in clinical studies for the treatment of CD44v6-expressing solid tumors. The candidate combines the therapeutic radioisotope nca Lu-177 with a proprietary antibody targeting CD44v6. CD...

2026-08-20

Automatic Radiation Environment Monitoring Station in Mianyang, Sichuan Put into Trial Operation, with Core Equipment and Systems Achieving Domestic Localization

Recently, the automatic radiation environment monitoring station located within the Nuclear Medical Health Industrial Park of the China (Mianyang) Science and Technology City was officially put into trial operation. As the first automatic radiation environment monitoring station in Sichuan Province to fully achieve domestic localization of core equipment and systems, it will provide radiation environment safety assurance for the development of the nuclear medical industry in the park through 24-hour uninterrupted automatic monitoring capabilities. At the automatic radiation environment monitoring station, operational data from equipment such as environmental γ dose rate monitors are updated in real time on monitoring screens. Compared with the previous approach that relied on manual on-site sampling and batch laboratory analysis, the automatic station enables continuous monitoring, reducing the time required to produce monitoring results from several days to the same day, thereby improving...

2026-08-20